Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well tandutinib works in treating patients who have
undergone surgery for metastatic kidney cancer. Tandutinib may stop the growth of kidney
cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to
the tumor. Giving tandutinib after surgery may kill any tumor cells that remain after
surgery.